LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) today announced the pricing of its initial public offering of 4,400,000 shares of its common stock at a price to the public of $16.00 per share. The shares of KYTHERA's common stock will trade on the NASDAQ Global Select Market under the symbol "KYTH." All of the shares of common stock are being offered by KYTHERA. In addition, KYTHERA has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock to cover over-allotments, if any.
The offering is expected to close on October 16, 2012, subject to customary closing conditions.
J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Leerink Swann LLC is acting as lead co-manager and Lazard Capital Markets LLC is acting as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 10, 2012. Copies of the registration statement, as amended, can be accessed through the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
The offering will be made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204; or Goldman, Sachs & Co., Prospectus Department, 200 West Street, New York, NY 10282, by calling toll-free (866) 471-2526, by facsimile (212) 902-9316 or by emailing firstname.lastname@example.org.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is an injectable drug currently in Phase III clinical development for the reduction of submental fat, which commonly presents as a “double chin.”
KYTHERA Biopharmaceuticals, Inc.
Tel: (818) 587-4559